Pharmaceutical and medical device industry veteran Jacqueline Keller joins Neurochase as the company prepares to bring its pioneering CED drug delivery device for CNS indications to market –

Neurochase has today (Thursday, March 6) confirmed the appointment of Jacqueline Keller as the company’s Chief Marketing Officer with immediate effect. 

With more than 20 years’ experience in the medical device industry, Jacqueline will play a key strategic role in helping Neurochase support its pharmaceutical and biotech partners to bring their treatments to market in combination with the company’s pioneering Convection Enhanced Delivery (CED) system*. 

Jacquie joins the Neurochase team having spent five years as a Vice President of Marketing at ClearPoint Neuro. During her time at the US-based company, she spearheaded the global initiative that led to the EU and FDA approvals of the combination gene therapy and drug delivery device authorized to deliver the first-ever approved gene therapy available to treat the devastating inherited paediatric neurological disorder, AADC Deficiency.

Prior to joining ClearPoint, Jacquie spent more than 15 years helping novel medical device technologies in the cardiology and oncology space cross the adoption chasm in North America, Europe, Latin America and Asia-Pacific at major medical device companies including Philips and Volcano Corporation.

San Diego-based Jacquie said of her appointment: “The sheer volume of gene and cell therapies that are currently in the pipeline to treat neurological disorders will demand delivery platforms and paradigms that are fast, accurate, and scalable. 

“I believe the premier targeted delivery approach developed by Neurochase represents a significant advancement in the field. I am excited to leverage my expertise and collaborate with our partners to commercialize this truly groundbreaking technology.”

Sharon Kane, Chief Executive of Neurochase, said: “I am thrilled to welcome Jacquie to the team with her extensive knowledge and experience in the industry. Jacquie joins Neurochase at a pivotal time as we prepare to launch our intraparenchymal drug delivery platform to enable treatments for diseases of the Central Nervous System (CNS) later this year.   

“With the Neurochase delivery system currently being used in a number of pre-clinical programmes, Jaquie’s appointment will continue to further develop relationships with a number of key gene and cell therapy partners.” 

More…/

*For investigational use only. Not approved for clinical use in any geographyTo find out more about Neurochase visit: neurochase.com